Troriluzole for Obsessive-Compulsive Disorder

Recruiting in Palo Alto (17 mi)

+56 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Biohaven Pharmaceuticals, Inc.

Stay on your current meds

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing troriluzole to see if it can help people with OCD who haven't improved with common medications. Troriluzole works by balancing brain chemicals that may be causing OCD symptoms. The goal is to find a more effective treatment for those who need additional help.

Eligibility Criteria

This trial is for adults with Obsessive Compulsive Disorder (OCD) who haven't had enough improvement from certain medications like SSRIs or clomipramine. Participants must be medically stable, able to perform tests and interviews, understand English well, and agree to use two forms of contraception if applicable. They should have moderate to severe OCD symptoms despite current treatment but no other major psychiatric conditions that could affect their OCD assessment.

Inclusion Criteria

My current medication for OCD isn't working well, and my symptoms are severe.

I have at least 6 years of education and am fluent in English.

My health is stable based on recent exams and tests.

+9 more

Exclusion Criteria

Mini Mental State Examination (MMSE) score of < 24 at Screening

I do not have any mental or physical health conditions that could explain my OCD symptoms.

I have tried at least 3 different depression medications without success.

+10 more

Participant Groups

The study is testing the effectiveness of troriluzole as an additional treatment compared to a placebo in people with OCD who don’t respond well enough to standard treatments. Troriluzole's benefits will be evaluated alongside participants' ongoing medication regimens.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: TroriluzoleExperimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention